![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig1_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlemscd-31.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pse
![Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening | Scientific Reports Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-75319-8/MediaObjects/41598_2020_75319_Fig1_HTML.png)
Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening | Scientific Reports
![CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC) | British Journal of Cancer CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC) | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01431-9/MediaObjects/41416_2021_1431_Fig1_HTML.png)